Resistance profile and mechanism of severe acute respiratory syndrome coronavirus-2 variants to LCB1 inhibitor targeting the spike receptor-binding motif

LCB1 is a 56-mer miniprotein computationally designed to target the spike (S) receptor-binding motif of SARS-CoV-2 with potent in vitro and in vivo inhibitory activities (Cao et al., 2020; Case et al., 2021). However, the rapid emergence and epidemic of viral variants have greatly impacted the effec...

詳細記述

書誌詳細

出版年:	Frontiers in Microbiology
主要な著者:	Tong Wu, Yuanmei Zhu, Nian Liu, Yue Hu, Huihui Chong, Yuxian He
フォーマット:	論文
言語:	英語
出版事項:	Frontiers Media S.A. 2022-10-01
主題:	SARS-CoV-2 variants of concern entry inhibitor LCB1 drug resistance
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fmicb.2022.1022006/full